"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 0 | 2 |
| 1994 | 3 | 3 | 6 |
| 1995 | 3 | 0 | 3 |
| 1996 | 3 | 0 | 3 |
| 1997 | 4 | 0 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 2 | 3 |
| 2003 | 2 | 0 | 2 |
| 2004 | 5 | 0 | 5 |
| 2005 | 0 | 1 | 1 |
| 2006 | 3 | 2 | 5 |
| 2007 | 3 | 3 | 6 |
| 2008 | 3 | 0 | 3 |
| 2009 | 4 | 2 | 6 |
| 2010 | 15 | 1 | 16 |
| 2011 | 12 | 0 | 12 |
| 2012 | 10 | 0 | 10 |
| 2013 | 10 | 5 | 15 |
| 2014 | 6 | 3 | 9 |
| 2015 | 10 | 1 | 11 |
| 2016 | 3 | 0 | 3 |
| 2017 | 10 | 0 | 10 |
| 2018 | 6 | 2 | 8 |
| 2019 | 9 | 0 | 9 |
| 2020 | 4 | 0 | 4 |
| 2021 | 8 | 0 | 8 |
| 2022 | 3 | 0 | 3 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. Clin Cancer Res. 2023 Jul 14; 29(14):2651-2667.
-
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. Sci Adv. 2023 05 19; 9(20):eade7236.
-
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol. 2023 02 14; 25(2):339-350.
-
Glucose Infusion Induced Change in Intracellular pH and Its Relationship with Tumor Glycolysis in a C6 Rat Model of Glioblastoma. Mol Imaging Biol. 2023 04; 25(2):271-282.
-
Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022 06 03; 10(6):770-784.
-
Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. Ther Deliv. 2022 04; 13(4):249-273.
-
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021 11 02; 37(5):109957.
-
Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465.
-
Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence. Cancer Res. 2021 12 01; 81(23):5935-5947.
-
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.